Core Viewpoint - The A-share market shows a slight decline with the Shanghai Composite Index closing at 3500.62 points, just above the six-month moving average, indicating a mixed sentiment among investors [1] Group 1: Market Performance - The total trading volume of A-shares reached 9269.95 billion yuan today [1] - The Shanghai Composite Index experienced a change of -0.12% [1] Group 2: Stocks Breaking the Six-Month Line - A total of 149 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Puyuan Information with a deviation rate of 19.21% and a price increase of 20.01% [1] - Changyuan Donggu with a deviation rate of 9.24% and a price increase of 10.02% [1] - Rundu Co., Ltd. with a deviation rate of 8.75% and a price increase of 10.03% [1] Group 3: Stocks with Smaller Deviation Rates - Stocks such as Anku Technology, Meishi Technology, and Saiwei Electronics have just crossed the six-month line with smaller deviation rates [1]

创新药概念股集体调整， 塞力医疗、 联环药业跌停， 常山药业、 哈三联、 润都股份、 泓博医药、 北 陆药业、 昂利康、 舒泰神等跌超5%。 ...

Group 1 - The company expects a net loss for the period from January 1, 2025, to June 30, 2025, with an estimated loss ranging from 30 million to 39 million yuan, compared to a profit of 37.8015 million yuan in the same period last year, representing a decline of 179.36% to 203.17% [1] - The company anticipates a net profit attributable to shareholders of the listed company to be between a loss of 38 million to 46 million yuan, with a significant decrease in net profit after deducting non-recurring gains and losses, expected to be a loss of 38 million to 46 million yuan compared to a profit of 31.4786 million yuan last year, reflecting a decline of 220.72% to 246.13% [1] - Basic earnings per share are projected to be a loss of 0.09 to 0.12 yuan per share, compared to a profit of 0.11 yuan per share in the previous year [1] Group 2 - The main reasons for the performance decline include the impact of pharmaceutical industry policies and market factors, particularly the national centralized procurement policy, which led to a significant decrease in sales volume of the main profit-generating product, Rabeprazole Sodium Enteric-coated Capsules, as well as varying impacts on sales volume and prices of other major formulation products, resulting in a decline in gross profit [1] - The sales prices of major raw materials have also significantly decreased due to domestic and international market competition, contributing to a decline in both operating revenue and product profitability compared to the previous year [1]

[Current Period Performance Forecast](index=1&type=section&id=I.%20Current%20Period%20Performance%20Forecast) The company forecasts a net loss for the first half of 2025, with significant declines in net profit attributable to shareholders and non-recurring net profit [Forecast Period](index=1&type=section&id=%28I%29%20Forecast%20Period) This performance forecast covers the period from January 1, 2025, to June 30, 2025 - The performance forecast period is from January 1, 2025, to June 30, 2025[2](index=2&type=chunk) [Performance Forecast Details](index=1&type=section&id=%28II%29%20Performance%20Forecast%20Details) The company expects a net loss for the first half of 2025, with both net profit attributable to shareholders and non-recurring net profit turning from profit to loss, and basic earnings per share also becoming a loss Key Financial Indicators for H1 2025 Performance Forecast | Item | Current Period Forecast (CNY 10,000) | Prior Period (CNY 10,000) | Year-over-Year Change (%) | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of Listed Company | Loss: 3,000 – 3,900 | Profit: 3,780.15 | Decrease: 179.36% – 203.17% | | Net Profit After Deducting Non-recurring Gains and Losses | Loss: 3,800 – 4,600 | Profit: 3,147.86 | Decrease: 220.72% – 246.13% | | Basic Earnings Per Share (CNY/share) | Loss: 0.09 – 0.12 | Profit: 0.11 | - | [Communication with Accounting Firm](index=1&type=section&id=II.%20Communication%20with%20Accounting%20Firm) The company has pre-communicated with its accounting firm regarding the unaudited performance forecast data, with no significant disagreements identified [Communication Results](index=1&type=section&id=Communication%20Results) The current performance forecast data is unaudited, but the company has pre-communicated with the accounting firm, and both parties have no significant disagreements regarding the forecast - The financial data related to the performance forecast has not been audited by the accounting firm[3](index=3&type=chunk) - The company has pre-communicated with the accounting firm regarding the performance forecast, and there are no significant disagreements between the parties[3](index=3&type=chunk) [Explanation of Performance Changes](index=1&type=section&id=III.%20Explanation%20of%20Performance%20Changes) Performance decline is primarily due to pharmaceutical industry policies and market competition, leading to decreased sales volume and price for key preparations, significant gross margin reduction, and lower raw material drug prices [Key Influencing Factors](index=1&type=section&id=Key%20Influencing%20Factors) The performance decline is mainly attributed to pharmaceutical industry policies (national centralized procurement) and market competition, resulting in a significant drop in sales volume and price for key preparation products, a substantial decrease in gross profit, and a notable reduction in raw material drug product sales prices, collectively leading to a significant year-over-year decrease in operating revenue and profitability - Sales volume of Rabeprazole Sodium Enteric-coated Capsules, a key profitable preparation product, significantly decreased due to pharmaceutical industry policies, especially national centralized procurement, and market factors[4](index=4&type=chunk) - Sales volume and prices of other major preparation products were also affected to varying degrees, leading to a decline in gross margin[4](index=4&type=chunk) - Due to domestic and international market competition, sales prices of key raw material drug products significantly decreased, resulting in a year-over-year decline in operating revenue and product profitability[4](index=4&type=chunk) [Risk Warning](index=1&type=section&id=IV.%20Risk%20Warning) The company advises investors that the performance forecast data is preliminary, and final financial figures will be based on the officially disclosed H1 2025 report [Investment Risk Disclosure](index=2&type=section&id=Investment%20Risk%20Disclosure) The company reminds investors that this performance forecast data is a preliminary calculation result, and the final financial data will be subject to the officially disclosed 2025 semi-annual report; investors are advised to be aware of investment risks - The forecast data is preliminary, and specific financial data will be subject to the company's officially disclosed 2025 semi-annual report[6](index=6&type=chunk) - Investors are kindly reminded to be aware of investment risks[6](index=6&type=chunk)

润都股份（002923）公告，预计2025年上半年净利润亏损3000万元–3900万元，上年同期盈利3780.15万 元，同比下降179.36%-203.17%。 ...

Group 1: Sales and Market Performance - The sales of nicotine at the company's Jingmen facility have significantly increased compared to the same period last year, although this has not yet had a major impact on the overall business performance [1] - The sales of the antihypertensive drug, Rabeprazole enteric-coated capsules, have declined, which has significantly affected the company's performance [4] - The market competition for Sartans remains intense, with sales prices fluctuating in a low range due to various factors including supply and demand [5] Group 2: Product Development and Innovation - The company's Class 1 innovative drug, Dihydrocodeine injection, is classified as a chemical drug and is used for myocardial perfusion imaging (MPI) to diagnose and assess myocardial ischemia [2] - The core formulation product matrix covers various therapeutic areas including cardiovascular, digestive, analgesic, anti-infective, endocrine, respiratory, and anesthesia, with a focus on innovative dosage forms [3] - The company is committed to advancing green and synthetic biotechnology applications, accelerating the development and launch of generic and innovative drugs, particularly in cardiovascular and digestive systems [4] Group 3: Safety and Usage Guidelines - Dihydrocodeine injection has a good safety profile with mild adverse reactions that quickly resolve after discontinuation, making it suitable for use in myocardial perfusion imaging [2] - The specific usage of Dihydrocodeine injection should be determined by doctors based on individual patient conditions, adhering strictly to medical advice [2]

Group 1 - The Artemisinin concept index increased by 0.65%, ranking 10th among concept sectors, with four stocks rising, including Haizheng Pharmaceutical which hit the daily limit, and Zhejiang Medicine, Huaren Shuanghe, and Baiyunshan also showing gains of 0.79%, 0.69%, and 0.08% respectively [1] - The leading decliners in the sector included Rundu Co., New Harmony, and Kunming Pharmaceutical, which fell by 1.41%, 1.36%, and 1.17% respectively [1] - The net inflow of main funds into the Artemisinin concept sector was 95 million yuan, with Haizheng Pharmaceutical receiving the highest net inflow of 105 million yuan, followed by Zhejiang Medicine, New Harmony, and Baihua Pharmaceutical with net inflows of 25.71 million yuan, 9.91 million yuan, and 2.14 million yuan respectively [2][3] Group 2 - In terms of fund inflow ratios, Haizheng Pharmaceutical, Zhejiang Medicine, and Baihua Pharmaceutical had the highest net inflow rates of 9.03%, 5.48%, and 2.27% respectively [3] - The trading performance of key stocks in the Artemisinin concept included Haizheng Pharmaceutical with a daily increase of 10.02% and a turnover rate of 9.22%, while Zhejiang Medicine rose by 0.79% with a turnover rate of 3.19% [3][4] - Other stocks such as New Harmony and Baihua Pharmaceutical experienced declines of 1.36% and 0.41% respectively, with turnover rates of 1.04% and 3.34% [3][4]

Group 1 - Shengde Xintai won a bid for a thermal power steel pipe project worth approximately 217 million yuan, accounting for 8.15% of its audited revenue for 2024 [1] - High-speed Electric's subsidiary won a project for the Shanghai-Nanjing-Hefei high-speed railway, with a bid amount of 71.76 million yuan [1] - Cangge Mining's subsidiary received a construction permit for a lithium-boron mining project, with a construction area of 106,900 square meters [2] Group 2 - China Electric Power Construction signed a mining transportation project contract in Guinea worth approximately 5.063 billion yuan, with a total duration of about 72 months [3] - Guobang Pharmaceutical's subsidiary completed the registration of an equity investment fund focusing on strategic emerging industries [4] - Deshi Co. obtained two invention patents related to oil and gas field development [5][26] Group 3 - Xue Tian Salt Industry expects a significant decrease in net profit for the first half of 2025, projecting a decline of 76.34% to 80.29% [6] - Rundu Co. received a drug registration certificate for moxifloxacin hydrochloride tablets, used for treating various bacterial infections [7] - China Nuclear Power reported a 15.65% increase in power generation in the first half of the year, with nuclear power generation up by 12.01% [8] Group 4 - Suqian Liansheng obtained two invention patents related to wastewater treatment methods [9] - Boshi Co. signed a 109 million yuan operation and maintenance service contract for solid product packaging [11] - *ST Sailong's subsidiary received a drug registration certificate for torasemide injection, used for various medical conditions [13] Group 5 - North Bay Port reported a 10.95% increase in cargo throughput for the first half of 2025, with container throughput also showing growth [14] - Kaiwei Te expects a revenue increase of 56.17% to 90.87% for the first half of 2025 [15] - Wankai New Materials plans to reduce production and conduct maintenance on 60,000 tons of PET capacity, affecting overall performance [16] Group 6 - Haiwang Bio's HW130 injection successfully completed Phase I clinical trials, showing good safety and tolerability [19] - Zhenai Meijia received a total of 22.8 million yuan in compensation for land acquisition, which will significantly impact its 2025 performance [20] - Changyuan Electric reported a 23.58% decrease in power generation in June, with a notable decline in thermal power generation [21] Group 7 - Shouxiangu's subsidiary completed the registration of two health food products [22] - Kailun Co. announced the resignation of its deputy general manager and board secretary [23] - Xibu Muye reported a 2.15% year-on-year increase in fresh milk production in June [24] Group 8 - Deshi Co. obtained two invention patents related to oil and gas field development [26] - Jingwei Huikai plans to acquire a 12.44% stake in Nuo Si Micro for 149 million yuan [27] - Electric Alloy completed the registration of its subsidiary in Mexico [29] Group 9 - Meinuohua expects a net profit increase of 142.84% to 174.52% for the first half of 2025 [30] - Guizhou Moutai repurchased approximately 3.38 million shares, accounting for 0.2692% of its total share capital [31][32] - Warner Pharmaceutical received approval for the listing application of a raw material drug for treating respiratory diseases [34] Group 10 - Yuan Dong Bio's independent director is under investigation for serious violations [35] - Dash Intelligent signed a contract for a smart project worth 11.88 million yuan [36] - Dayou Energy plans to transfer 586,500 tons of coal production capacity replacement indicators [37] Group 11 - Foton Motor reported a 150.96% increase in new energy vehicle sales in the first half of 2025 [39] - Renfu Pharmaceutical's shareholder plans to increase its stake by 1% to 2% [40] - Zongshen Power expects a net profit increase of 70% to 100% for the first half of 2025 [42] Group 12 - Yingboer plans to sell its wholly-owned subsidiary for 239 million yuan [44] - Changan Automobile reported a 1.59% increase in total vehicle sales in the first half of 2025 [46] - Fulian Precision signed a cooperation framework agreement with Sichuan Development Longmang [48] Group 13 - Nengte Technology plans to repurchase shares worth 300 million to 500 million yuan [50] - Longsoft Technology's controlling shareholder donated 3.43% of the company's shares [51] - Data Port's shareholders plan to reduce their holdings by up to 2% [52]

证券代码：002923 证券简称：润都股份 公告编号：2025-029 珠海润都制药股份有限公司 关于盐酸莫西沙星片获得药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 珠海润都制药股份有限公司（以下简称"公司"或"本公司"）近日收到国 家药品监督管理局签发的《药品注册证书》。现将有关情况公告如下： 一、药品基本情况 药品名称：盐酸莫西沙星片（以下简称"本品"） 剂型：片剂 申请事项：药品注册(境内生产) 规格：0.4g（按C₂₁H₂₄FN₃O₄计） 受理号：CYHS2302288 证书编号：2025S01982 药品批准文号：国药准字H20254689 药品注册标准编号：YBH15032025 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。 二、药品的适应症 为了减少耐药细菌的发生，保持盐酸莫西沙星和其他抗菌药物的有效性，盐 酸莫西沙星应该仅用于治疗已被证明或强烈怀疑由敏感细菌引起的感染。 在取得培养和药敏信息的情况下，应 ...

证券代码：002923 证券简称：润都股份 公告编号：2025-028 珠海润都制药股份有限公司 关于公司控股股东及共同实际控制人部分股份 解除质押及质押延期的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、股东部分股份解除质押及质押延期基本情况 珠海润都制药股份有限公司（以下简称"公司"）近日接到公司控股股东及共同 实际控制人之一李希先生的告知函，获悉李希先生将其所持有的本公司部分股份解 除质押和质押延期一事，具体情况如下： | | | | 东 | (股) | 比例 | 质押股份数 | 质押股份数 | 所持 | 司总 | 已质押股份 | 占已质 | 未质押股 | 占未 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名 | | (%) | 量（股） | 量（股） | 有股 | 股本 | 限售和冻 | 押股份 | 份限售和 | 质押股 | | 称 | | | | | 份比 | 比例 | 结、标记数 | 比例 | 冻结数量 | 份比例 | | | | | | ...